Chronic Hepatitis C Poses Silent but Deadly Liver Risks in the US

Chronic hepatitis C remains a serious health issue in the US, with an estimated 2.4 million people affected between 2013 and 2016. Unlike hepatitis A and B, no vaccine exists for this contagious virus, which spreads through contact with infected blood or shared needles. The disease is caused by the hepatitis C virus (HCV), which often shows no symptoms in its early stages. Over time, untreated infection can scar the liver, leading to cirrhosis—the most common complication. This scarring impairs liver function and may result in liver failure or cancer.

The standard treatment involves direct-acting antivirals (DAAs). These drugs work by targeting specific parts of the HCV replication process. By blocking the virus from multiplying, DAAs help clear the infection and prevent further damage. Without treatment, chronic hepatitis C can become life-threatening. Early detection and medical intervention are crucial to avoiding severe liver disease.

While hepatitis C has no vaccine, effective treatments like DAAs offer hope for those infected. Left unchecked, the virus can cause irreversible liver damage, making awareness and timely care essential. Public health efforts continue to focus on prevention and access to antiviral therapies.